1036209-06-9

Upstream product

• 675-10-5 4-hydroxy-6-methyl-2-pyron 
• 4441-50-3 β-cyclohexylalanine 

Downstream Products

• 1036209-07-0 C₁₇H₂₅NO₄ 
• 1036204-92-8 3-cyclohexyl-2-(4-hydroxy-6-methyl-2-oxopyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamide trifluoroacetate 
• 1036209-08-1 C₁₆H₂₃NO₄ 
• 1036209-10-5 C₁₆H₂₂ClNO₃ 
• 1036209-12-7 C₁₇H₂₅NO₃S 
• 1036209-13-8 C₁₆H₂₃NO₅S 
• 1036209-11-6 C₁₇H₂₅NO₅S 
• 1428663-25-5 C₁₈H₂₇NO₅S 
• 1428663-26-6 C₂₁H₃₁NO₅S 
• 1036204-95-1 3-cyclohexyl-2-(6-methyl-4-(methylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamide 
• 1036204-97-3 3-cyclohexyl-2-(4-(ethylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamide 
• 1036204-99-5 3-cyclohexyl-2-(4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamide 
• 1036209-15-0 C₁₉H₂₅N₃O₄S₂ 
• 1036209-14-9 C₁₉H₂₅N₃O₄S₂ 

Relevant academic research and scientific papers

Design, synthesis and SAR of novel glucokinase activators

Guided by co-crystal structures of compounds 15, 22 and 30, an SBDD approach led to the discovery of the 6-methyl pyridone series as a novel class of GKAs that potently activate GK in enzyme and cell assays. Anti-diabetic OGTT efficacy was demonstrated with 54 in a mouse model of type 2 diabetes.

GLUCOKINASE ACTIVATORS

Compounds of the following formula are provided for use with glucokinase: STR, wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds